• Home
  • Patrick Vermersch
Patrick Vermersch

Patrick Vermersch
university of Lille, Lille, France

About

699
Publications
65,767
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
21,318
Citations
Introduction
Skills and Expertise

Publications

Publications (699)
Article
Full-text available
Background Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS. Methods Post hoc analysis of...
Article
Background In the Phase 3 EXPAND study, siponimod reduced the Neurostatus-EDSS-measured risk of 3/6-month (M) confirmed disability progression versus placebo by 21%/26%, with more pronounced effects (31%/37%) in active SPMS (aSPMS). Here we evaluated the contribution of the Ambulation Score (AS) to measuring siponimod’s effect on disability progres...
Article
What is this summary about? This article summarizes the findings from a previously published article in Current Medical Research and Opinion. Cladribine tablets are an oral treatment for relapsing multiple sclerosis (shortened to MS), that are given for 4 periods of 4 to 5 days over 2 years (for a total of 20 days). In this analysis, researchers lo...
Article
Full-text available
Background and objectives: The onset of action for high-efficacy immunotherapies in multiple sclerosis (MS) is an important parameter. This study (MAGNIFY-MS) evaluates the onset of action of cladribine tablets by observing changes in combined unique active (CUA) MRI lesion counts during the first 6 months of treatment in patients with highly acti...
Article
Full-text available
Background and Objectives Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast cells and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS). Study AB07002 assessed oral masitinib in patients with progressive MS who were progressing but not clinically active. Methods This ra...
Article
Background Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in secondary progressive multiple sclerosis (SPMS) patients in the Phase 3 EXPAND study. Objective The...
Article
Les avancées thérapeutiques dans la sclérose en plaques (SEP) ont été importantes ces 3 dernières décennies. Les progrès en immunologie, la collaboration entre le milieu académique et industriel y ont contribué largement. La radiologie et plus spécialement l’imagerie par résonance nucléaire a bien montré, avec la clinique, l’effet de différents tra...
Article
Introduction Les fumarates présentent un profil bénéfice-risque favorable chez les patients atteints de sclérose en plaques récurrente-rémittente (SEP-RR). Une lymphopénie sévère et prolongée apparaît chez 2,2 % des patients. Objectifs L’objectif principal de LymphoTEC, étude rétrospective et multicentrique, est de décrire la reconstitution lympho...
Article
Introduction L’étude de phase IIIb CASTING évalue l’efficacité et la tolérance d’OCR chez des patients (pts) SEP-RR ayant une réponse sous-optimale à 1 ou 2 DMT pris ≥ 6 mois. LIBERTO est une étude d’extension ouverte dans laquelle les pts de CASTING peuvent être inclus. Objectifs Évaluer l’efficacité et la tolérance d’OCR à 3 ans chez les pts att...
Article
Introduction À l’issue d’un traitement de première ligne de la SEP un choix s’offre entre traitement de seconde ligne ou prescription d’un autre traitement de première ligne. Objectifs Décrire les modifications de traitement survenant en vie réelle après une première ligne de traitement de fond pour une SEP-RR. Patients et méthodes L’étude a été...
Article
Introduction La SEP-pédiatrique représente environ 5 % des cas. Son évolution est souvent plus active que chez l’adulte. Le profil d’efficacité et sécurité du DMF, établi chez l’adulte, est inconnu chez l’enfant. Objectifs L’étude CONNECT a comparé l’efficacité et la sécurité du DMF et de l’interféron bêta-1a (IFNβ-1a) intramusculaire chez des pat...
Article
Full-text available
Background Magnetic resonance imaging (MRI) measurements of gray matter (GM) atrophy and magnetization transfer ratio (MTR; correlate of myelination) may provide better insights than conventional MRI regarding brain tissue integrity/myelination in multiple sclerosis (MS). Objective To examine the effect of siponimod in the EXPAND trial on whole-br...
Article
Full-text available
On 12 September 2019, the global Patient Reported Outcome for Multiple Sclerosis (PROMS) Initiative was launched at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The multi-stakeholder PROMS Initiative is jointly led by the European Charcot Foundation (ECF) and the Multiple Sclerosis Internat...
Article
Introduction: It is important to confirm the effectiveness and tolerability of disease-modifying treatments for relapsing-remitting multiple sclerosis (RRMS) in real-world treatment settings. This prospective observational cohort study (VIRGILE) was performed at the request of the French health authorities. The primary objective was to evaluate th...
Article
Full-text available
Background: Cognitive deficits are common in multiple sclerosis (MS) and affect patients at all stages of the disease, regardless of phenotype. Aims: This literature review focuses the cognitive deficits observed in secondary progressive MS (SPMS). It is mainly based on studies that compared the frequency and main characteristics of cognitive de...
Article
Full-text available
Cladribine tablets (CladT) preferentially reduce B and T lymphocyte levels. As aging is associated with a decline in immune function, the effect of CladT on lymphocyte levels may differ by age. This post hoc analysis combined data from the Phase 3 CLARITY, CLARITY Extension, and ORACLE-MS studies to examine the effect of age (≤50 or >50 years) on l...
Article
Introduction Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. Case series...
Article
Full-text available
Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and 395/1120 (35.3%) without preexisting autoimmunity developed non-MS autoimmunity. Thyroid autoimmun...
Article
Full-text available
Background Gaps in current evidence and guidance leave clinicians with unanswered questions on the use of cladribine tablets for the treatment of multiple sclerosis (MS) in the era of the COVID-19 pandemic, in particular relating to COVID-19 vaccination. Objective We describe a consensus-based program led by international MS experts with the aim o...
Article
Full-text available
Objective To evaluate changes over 3 years in the thickness of inner retinal layers including the peripapillary retinal nerve fiber layer (pRNFL), and combined macular ganglion cell and inner plexiform layers (mGCIPL), in individuals with relapsing-remitting multiple sclerosis (RRMS) versus healthy controls; to determine whether optical coherence t...
Article
Full-text available
Background Using the treatment goal of ‘no evidence of disease activity’ (NEDA) incorporating MRI rebaselining, we assessed the efficacy of ocrelizumab in patients with relapsing–remitting multiple sclerosis with a prior suboptimal response, defined by MRI or relapse criteria, to one or two disease-modifying therapies (DMTs). Methods CASTING was a...
Poster
Full-text available
Introduction: Younger age, oligoclonal bands, infratentorial, and presence of spinal cord lesions are factors associated with an increased 10-year risk of clinical conversion from radiologically isolated syndrome (RIS). Whether disease-modifying therapy is beneficial in RIS remains currently unknown. Objectives: To evaluate the 2-year risk of a cli...
Article
Full-text available
Background: No evidence of disease activity (NEDA-3) is a patient-centric outcome increasingly used as the goal of multiple sclerosis treatment. Objective: Determine treatment durability of cladribine tablets beyond 2 years considering the variable bridging interval of 0.1-116.0 weeks between CLARITY and CLARITY Extension. Methods: Between CLA...
Article
Full-text available
Importance: Younger age, oligoclonal bands, and infratentorial and spinal cord lesions are factors associated with an increased 10-year risk of clinical conversion from radiologically isolated syndrome (RIS) to multiple sclerosis (MS). Whether disease-modifying therapy is beneficial for individuals with RIS is currently unknown. Objectives: To e...
Article
Full-text available
Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis. We aimed to determine the dose-response relationship between tolebrutinib and the reduction in new active br...
Article
Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton’s tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis. We aimed to determine the dose-response relationship between tolebrutinib and the reduction in new active br...
Article
Background Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). Objective Evaluate laquinimod’s efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS). Methods CONCERTO was a randomized, double-blind, placebo-controlled, phase-3 study. RRMS patients were randomized...
Article
Full-text available
Introduction: In the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study, cladribine tablets significantly reduced relapse rates and improved findings on magnetic resonance imaging versus placebo in patients with relapsing multiple sclerosis. In the CLARITY Extension study, treatment with cladribine tablets for 2 years followed b...
Article
Background Gait initiation is an automatized motor program that is preceded by anticipatory postural adjustments (APAs). During attentional tasks, these APAs can be modulated, producing multiple APAs. However, the role of the peripheral nervous system in the regulation of these APAs is unknown. Research question The objective of our study was to i...
Article
Full-text available
Objectives: The study aimed to assess the potential for serum neurofilament light chain (NFL) levels to predict the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab (NTZ)-treated patients with multiple sclerosis (MS) and to discriminate PML from MS relapses. Methods: NFL levels were measured with single molecule array (Sim...
Article
Full-text available
Background: It is thought that older patients with multiple sclerosis (MS) may present with a different clinical disease phenotype, and therefore respond to subcutaneous interferon beta-1a (sc IFN β-1a) differently to younger patients. However, few real-world data are available concerning the effectiveness of sc IFN β-1a according to age. Using dat...
Article
Full-text available
Background Evidence suggests that efficacy and safety of disease-modifying treatments for multiple sclerosis may differ with age. We evaluate efficacy and safety of teriflunomide across age subgroups of patients from pooled clinical trials and real-world studies. Methods Post hoc analyses of patients who received teriflunomide 14 mg in the pooled...
Preprint
Full-text available
Background: Gaps in current evidence and guidance leave clinicians with unanswered questions on the use of cladribine tablets for the treatment of multiple sclerosis (MS) in the era of the COVID 19 pandemic, in particular relating to COVID 19 vaccination. Objective: We describe a consensus-based programme led by international MS experts with the ai...
Article
Full-text available
Introduction: In the 2-year CARE-MS trials (NCT00530348; NCT00548405) in patients with relapsing-remitting multiple sclerosis, alemtuzumab showed superior efficacy versus subcutaneous interferon beta-1a. Efficacy was maintained in two consecutive extensions (NCT00930553; NCT02255656). This post hoc analysis compared disability outcomes over 9 year...
Article
Background: In multiple sclerosis (MS), the prevalence of alexithymia, defined as an inability to identify and describe emotions, is close to 50% but the prevalence of this symptom in clinically isolated syndrome (CIS) is unknown. Characterizing alexithymia at an early stage of the disease can help to clarify psychobehavioural disturbances in CIS...
Article
Full-text available
Artificial intelligence (AI)-based diagnostic algorithms have achieved ambitious aims through automated image pattern recognition. For neurological disorders, this includes neurodegeneration and inflammation. Scalable imaging technology for big data in neurology is optical coherence tomography (OCT). We highlight that OCT changes observed in the re...
Preprint
BACKGROUND A digital tool (Multiple Sclerosis Progression Discussion tool, MSProDiscuss) was developed to facilitate a discussion between a healthcare professional (HCP) and patient in evaluating early, subtle signs of multiple sclerosis (MS) disease progression. OBJECTIVE To report findings on the usability and usefulness testing of the MSProDisc...
Article
Background A digital tool, Multiple Sclerosis Progression Discussion Tool (MSProDiscuss), was developed to facilitate discussions between health care professionals (HCPs) and patients in evaluating early, subtle signs of multiple sclerosis (MS) disease progression. Objective The aim of this study is to report the findings on the usability and usef...
Article
Introduction L’étude de phase IIIb CASTING évalue l’efficacité d’OCR sur l’activité de la maladie et sa tolérance chez les patients (pts) atteints de SEP-RR qui ont eu une réponse inadéquate à 1 ou 2 DMTs antérieur(s) (1/2 DMT). Objectifs Présenter les résultats à 2 ans de l’efficacité d’OCR sur l’absence d’activité de la maladie évaluée avec le s...
Article
Introduction SymptoMScreen est un outil d’évaluation utilisé dans l’étude CASTING en cours, étude de phase IIIb à un seul bras, menée en ouvert chez des patients (pts) atteints de SEP-RR qui ont eu une réponse sous-optimale à 1 ou 2 DMT antérieur. Objectifs Présenter l’évolution des scores SymptoMScreen rapportés par les pts sur l’évaluation de 12...
Article
Introduction Une étude récente a montré que les traitements oraux amélioraient, en vie réelle, le maintien et l’observance du traitement par rapport aux injectables chez les patients naïfs atteints de SEP. Objectifs Un des objectifs de cette étude consistait à décrire le parcours et les consommations de soins des patients en première ligne de trai...
Article
Introduction La sclérose en plaques (SEP) est une cause majeure de diminution de la capacité à travailler. Natalizumab est associé à une amélioration de la productivité dans des études observationnelles précédentes. Objectifs Évaluer l’impact du natalizumab sur l’évolution de la productivité au travail de patients actifs atteints de SEP RR en Fran...
Article
Introduction Plusieurs évaluations de routine (EDSS, poussées, IRM) sont prédictives de l’efficacité des traitements dans la sclérose en plaques récurrente-rémittente (SEP RR). Cependant, une évaluation multimodale fine a peu été étudiée. Objectifs Évaluer l’intérêt de plusieurs évaluations non pratiquées en routine sur le recours à un traitement...
Article
Introduction La fatigue est fréquente chez les patients atteints de sclérose en plaques (SEP) et altère la qualité de vie. Si certaines hypothèses éthio-pathogéniques ont été avancées aucune n’a été validée. Objectifs L’objectif de cette étude est de rechercher un lien entre la fatigue, les habitudes alimentaires et l’état nutritionnel des patient...
Article
Background: Disease modifying therapies (DMTs), have an impact on relapses and disease progression. Nonetheless, many patients with multiple sclerosis (pwMS) remain untreated. The objective of the present study was to determine the proportion of untreated patients with multiple sclerosis (pwMS) followed in expert centers in France and determine th...
Article
Full-text available
The Multiple Sclerosis Data Alliance (MSDA), a global multi-stakeholder collaboration, is working to accelerate research insights for innovative care and treatment for people with multiple sclerosis (MS) through better use of real-world data (RWD). Despite the increasing reliance on RWD, challenges and limitations complicate the generation, collect...
Article
Full-text available
Background : Relapsing–remitting multiple sclerosis (RRMS) patients with high disease activity (HDA) experience more severe disease than those without HDA. This analysis describes the efficacy of cladribine tablets 3.5 mg/kg in HDA patient subgroups that were either treated with disease-modifying drugs (DMDs) prior to study entry or were treatment...
Article
Objective: To investigate the effects of siponimod on cognitive processing speed (CPS) in secondary progressive (SP) multiple sclerosis (MS) patients, by means of a pre-defined exploratory, and post-hoc analysis of the EXPAND study, a randomized controlled trial (RCT) comparing siponimod and placebo. Methods: EXPAND was a double-blind, placebo-c...
Article
Full-text available
Background In the Phase 3, 96-week ORACLE-MS study, cladribine 10 mg tablets (3.5 mg/kg or 5.25 mg/kg cumulative dose over 2 years) significantly reduced the rate of conversion to clinically definite multiple sclerosis (CDMS) per the Poser criteria (henceforth referred to as CDMS), multiple sclerosis (MS) per the 2005 McDonald criteria, and the num...
Article
Full-text available
Background In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. Objective To distinguish siponimod’s direct effects on disability progression from those on relapses in the EXPAND phase 3 trial. Methods Three estimands, one based on principal stratum and two on hypothetical scen...
Article
Background: There are few head-to-head studies to compare highly active treatments in multiple sclerosis (MS). Objective: The aim of this study was to compare the effectiveness between natalizumab (NTZ) and fingolimod (FTY) in active relapsing-remitting MS. Method: Best Escalation STrategy in Multiple Sclerosis (BEST-MS) is a multicentric, pro...
Article
Full-text available
Background: In this pooled, post hoc analysis of a phase 2 trial and the phase 3 TEMSO, TOWER, and TENERE clinical trials, long-term efficacy and safety of teriflunomide were assessed in subgroups of patients with relapsing multiple sclerosis (MS) defined by prior treatment status. Methods: Patients were classified according to their prior treat...
Article
High-dose biotin (HDB) is a therapy used in non-active progressive multiple sclerosis (PMS). Several reports have suggested that HDB treatment may be associated with an increased risk of relapse. We aimed to determine whether HDB increases the risk of clinical relapse in PMS and describe the characteristics of the patients who experience it. We con...
Article
Background: Little is known about the use of first-line treatments for relapsing-remitting multiple sclerosis (RRMS), whether oral (teriflunomide and dimethyl fumarate) or injectable (interferons/glatiramer acetate [GA]) in France. We conducted an observational study to determine patient profile, persistence and compliance to first-line disease-mo...
Article
Introduction Cladribine 10 mg (dose cumulée de 3,5 mg/kg [CT3,5] sur 2 ans) a montré une efficacité versus placebo chez les patients atteints de sclérose en plaques récurrente-rémittente dans l’étude CLARITY (NCT00213135). Objectifs Analyse post-hoc pour évaluer les résultats d’efficacité chez les patients ayant précédemment utiliser un traitement...
Article
Introduction L’Evobrutinib, inhibiteur de la tyrosine kinase de Bruton (BTK), a démontré une efficacité clinique dans le traitement de la sclérose en plaques (SEP) au cours d’une étude de phase 2. Objectifs Étudier l’effet de l’Evobrutinib sur les cellules immunitaires et les immunoglobulines (Ig) sur une période de 48 semaines. Patients et métho...
Article
Introduction La satisfaction des patients est importante pour assurer l’adhésion thérapeutique. Dans CASTING, les pts avec SEP-RR, en réponse sous-optimale à un DMT et traités par OCR ont rempli un questionnaire de satisfaction sur 1 an. Objectifs Rapporter les changements de l’autoévaluation sur la satisfaction au traitement entre l’inclusion (BL...
Article
Full-text available
Introduction L’arsenal thérapeutique s’est enrichi dans le traitement des formes actives de sclérose en plaques (SEP), mais très peu d’études comparent les molécules de manière prospective. Objectifs L’étude BEST-MS a démarré en 2013 pour comparer de manière prospective l’efficacité de deux principales molécules disponibles à cette date pour les f...
Article
Introduction Les pts atteints de SEP-RR ont souvent une activité de la maladie malgré un DMT. L’étude de phase IIIb CASTING évalue l’efficacité/tolérance d’OCR chez les pts atteints de SEP-RR avec réponse inadéquate à 1/2 DMTs. Objectifs Présenter les Résultats intermédiaires à 1 an sur l’absence d’activité de la maladie (NEDA ; critère principal)...
Article
Introduction Par voie orale, cladribine 10 mg, dose cumulative de 3,5 mg/kg (CT3.5) sur 2 ans, est efficace versus placebo chez les patients atteints de sclérose en plaques (SEP) récurrente (CLARITY). Objectifs Explorer en post-hoc, la relation entre le score EDSS en début de traitement et le risque de progression en SEP secondairement progressive...
Article
Objective To evaluate the ability of intereye retinal thickness difference (IETD) measured by optical coherence tomography (OCT) to detect asymptomatic optic nerve involvement in clinically isolated syndrome (CIS). Methods We conducted a cross-sectional study of patients who recently presented a CIS (≤4.5 months). All patients underwent OCT and br...
Article
Background: Data are needed on long-term effect of natalizumab (NTZ) in relapsing-remitting multiple sclerosis (RRMS). Objectives: To evaluate the time of onset of secondary progressive phase in patients with an RRMS treated with NTZ and to investigate predictive factors. Methods: TYSTEN is an observational study. Patients starting NTZ between 20...